Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

In this 12-week, phase 2 trial, an anti–interleukin-17–receptor antibody was effective in treating moderate-to-severe psoriasis. Adverse events included neutropenia. Larger trials of longer duration are needed to assess the risk of infections. Psoriasis is a chronic T-cell–mediated autoimmune diseas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2012-03, Vol.366 (13), p.1181-1189
Hauptverfasser:	Papp, Kim A, Leonardi, Craig, Menter, Alan, Ortonne, Jean-Paul, Krueger, James G, Kricorian, Gregory, Aras, Girish, Li, Juan, Russell, Chris B, Thompson, Elizabeth H.Z, Baumgartner, Scott
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cytokines Dermatology Dose-Response Relationship, Drug Double-Blind Method Drug dosages Drug therapy Erythema Female General aspects Humans Immunotherapy Injections, Subcutaneous Interleukin 17 Light therapy Male Medical sciences Middle Aged Monoclonal antibodies Neutropenia Patients Psoriasis Psoriasis - drug therapy Psoriasis. Parapsoriasis. Lichen Receptors, Interleukin-17 - antagonists & inhibitors Receptors, Interleukin-17 - immunology Respiratory tract diseases Rhinopharyngitis Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!